The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Updates in newly diagnosed and R/R AML
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, shares some of the key updates in acute myeloid leukemia (AML) from the ASH 2021 meeting. In the newly diagnosed AML space, Dr Fathi comments on the AGILE (NCT03173248) and LACEWING (NCT02752035) trials. Several novel agents under investigation for relapsed/refractory (R/R) disease also sparked interest, including SNDX-5613, a potent, selective protein-protein interaction inhibitor of menin, and HM43239, a novel FLT3 inhibitor which additionally targets SYK. Finally, Dr Fathi highlights the Phase III QUAZAR study (NCT01757535) long-term follow-up results which demonstrated the benefits of oral azacitidine maintenance compared to placebo for prolonged overall survival. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
